Browse CCNG1

Summary
SymbolCCNG1
Namecyclin G1
Aliases CCNG; cyclin-G; Cyclin-G1
Chromosomal Location5q32-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Note=DNA replication foci after DNA damage.
Domain PF00134 Cyclin
Function

May play a role in growth regulation. Is associated with G2/M phase arrest in response to DNA damage. May be an intermediate by which p53 mediates its role as an inhibitor of cellular proliferation (By similarity).

> Gene Ontology
 
Biological Process GO:0000079 regulation of cyclin-dependent protein serine/threonine kinase activity
GO:0007067 mitotic nuclear division
GO:0071900 regulation of protein serine/threonine kinase activity
GO:1904029 regulation of cyclin-dependent protein kinase activity
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04115 p53 signaling pathway
Reactome R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-5633007: Regulation of TP53 Activity
R-HSA-6804757: Regulation of TP53 Degradation
R-HSA-6806003: Regulation of TP53 Expression and Degradation
R-HSA-3700989: Transcriptional Regulation by TP53
Summary
SymbolCCNG1
Namecyclin G1
Aliases CCNG; cyclin-G; Cyclin-G1
Chromosomal Location5q32-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CCNG1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCCNG1
Namecyclin G1
Aliases CCNG; cyclin-G; Cyclin-G1
Chromosomal Location5q32-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CCNG1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCCNG1
Namecyclin G1
Aliases CCNG; cyclin-G; Cyclin-G1
Chromosomal Location5q32-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CCNG1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.6690.0494
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4820.839
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.8010.663
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.030.945
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4040.801
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5720.756
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1620.73
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0710.972
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2830.902
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.5540.797
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.4610.887
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1220.181
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CCNG1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCCNG1
Namecyclin G1
Aliases CCNG; cyclin-G; Cyclin-G1
Chromosomal Location5q32-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CCNG1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCCNG1
Namecyclin G1
Aliases CCNG; cyclin-G; Cyclin-G1
Chromosomal Location5q32-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CCNG1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CCNG1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCCNG1
Namecyclin G1
Aliases CCNG; cyclin-G; Cyclin-G1
Chromosomal Location5q32-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CCNG1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCCNG1
Namecyclin G1
Aliases CCNG; cyclin-G; Cyclin-G1
Chromosomal Location5q32-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CCNG1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCCNG1
Namecyclin G1
Aliases CCNG; cyclin-G; Cyclin-G1
Chromosomal Location5q32-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CCNG1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCCNG1
Namecyclin G1
Aliases CCNG; cyclin-G; Cyclin-G1
Chromosomal Location5q32-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CCNG1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.